Changes in the serum level of matrix metalloproteinases and surfactant proteins in patients with hypersensitivity pneumonitis

The most studied biomarkers of progressive pulmonary fibrosis (PPF) are matrix metalloproteinases (MMP) types 1, 7 and 9 and surfactant proteins A and D (SP-A and SP-D). The aim was to study the levels of MMP-1, MMP-7, MMP-9, SP-A and SP-D in the context of diagnosis of idiopathic pulmonary fibrosis (IPF) and hypersensitivity pneumonitis (HP) and the relationship of these indicators with the PPF criteria. Methods. The study included 65 patients with ILD. Analysis of computed tomography (CT) scans, spirometry, and lung diffusion capacity data were performed. PPF was established based on the diagnostic criteria of the American Thoracic Society (2022). Quantitative determination of serum SP-A levels was performed using Cloud-Clone Corp. kits. (China), SP-D and MMP-7 levels using RDS kits (USA), MMP-1 and MMP-9 levels using RayBiotech kits (USA) on the Hydro Flex enzyme immunoassay (TECAN, Austria). Statistical data processing was performed using Statistica 10.0 software. Results. A relationship between elevated MMP-7 and SP-D levels in HP and PPF criteria was found. No statistically significant differences were found between MMP-7 and SP-D levels in IPF and HP with PPF (9.03 ± 3.1 and 8.47 ± 2.61 ng/ml, respectively; p = 0.42), as well as SP-D (34.51 ± 6.12 ng/ml in IPF and 33.22 ± 8.91 ng/ml in HP with PPF; p = 0.45). Negative correlation was noted between elevated levels of SP-D and MMP-7 with FVC and DLCO during the year. Conclusion. An increase in the levels of MMP-7 and SP-D in the blood serum allows us to consider these indicators for the diagnosis of PPF in HP.

1. Kuzubova N.A., Titova O.N., Skliarova D.V. [Interstital lung diseases with progressive pulmonary fibrosis: phatogenetic features and approaches to therapy]. Meditsinskiy sovet. 2020; (17): 99–106. DOI: 10.21518/2079-701X-2020-17-99-106 (in Russian).

2. Avdeev S.N., Chikina S.Yu., Tyurin I.E. et al. [Chronic fibrosing progressing interstitial lung disease: a decision of Multidisciplinary Expert Board]. Pul’monologiya. 2021; 31 (4): 505–510. DOI: 10.18093/0869-0189-2021-31-4-505-510 (in Russian).

3. Brovko M.Yu., Akulkina L.A., Sholomova V.I. et al. [A novel approach to the treatment of fibrosing interstitial lung diseases]. Klinicheskaya farmakologiya i terapiya. 2020; 29 (1): 61–66. DOI: 10.32756/0869-5490-2020-1-61-66 (in Russian).

4. Raghu G., Remy-Jardin M., Richeldi L. et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am. J. Respir. Crit. Care Med. 2022; 205 (9): e18–47. DOI: 10.1164/rccm.202202-0399ST.

5. Bowman W.S., Newton C.A., Linderholm A.L. et al. Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis. Lancet Respir. Med. 2022; 10 (6): 593–602. DOI: 10.1016/S2213-2600(21)00503-8.

6. Inoue Y., Kaner R.J., Guiot J. et al. Diagnostic and prognostic biomarkers for chronic fibrosing interstitial lung diseases with a progressive phenotype. Chest. 2020; 158 (2): 646–659. DOI: 10.1016/j.chest.2020.03.037.

7. Olson A.L., Patnaik P., Hartmann N. et al. Prevalence and incidence of chronic fibrosing interstitial lung diseases with a progressive phenotype in the United States estimated in a large claims database analysis. Adv. Ther. 2021; 38 (7): 4100–4114. DOI: 10.1007/s12325-021-01786-8.

8. Tzouvelekis A., Herazo-Maya J.D., Slade M. et al. Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis. Respirology. 2017; 22 (3): 486–493. DOI: 10.1111/resp.12920.

9. Guiot J., Moermans C., Henket M. et al. Blood biomarkers in idiopathic pulmonary fibrosis. Lung. 2017; 195 (3): 273–280. DOI: 10.1007/s00408-017-9993-5.

10. Majewski S., Szewczyk K., Żal A. et al. Serial measurements of circulating KL-6, SP-D, MMP-7, CA19-9, CA-125, CCL18, and periostin in patients with idiopathic pulmonary fibrosis receiving antifibrotic therapy: an exploratory study. J. Clin. Med. 2021; 10 (17): 3864. DOI: 10.3390/jcm10173864.

11. Olson A., Hartmann N., Patnaik P. et al. Estimation of the prevalence of progressive fibrosing interstitial lung diseases: systematic literature review and data from a physician survey. Adv. Ther. 2021; 38 (2): 854–867. DOI: 10.1007/s12325-020-01578-6.

12. Khan F.A., Stewart I., Saini G. et al. A systematic review of blood biomarkers with individual participant data meta-analysis of matrix metalloproteinase-7 in idiopathic pulmonary fibrosis. Eur. Respir. J. 2021; 59 (4): 2101612. DOI: 10.1183/13993003.01612-2021.

13. Bowman W.S., Echt G.A., Oldham J.M. Biomarkers in progressive fibrosing interstitial lung disease: optimizing diagnosis, prognosis, and treatment response. Front. Med. (Lausanne). 2021; 8: 680997. DOI: 10.3389/fmed.2021.680997.

14. White E.S., Xia M., Murray S. et al. Plasma surfactant protein-D, matrix metalloproteinase-7, and osteopontin index distinguishes idiopathic pulmonary fibrosis from other idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2016; 194 (10): 1242–1251. DOI: 10.1164/rccm.201505-0862OC.

15. Kayıkçı A., Alatas F., Alatas I.O. et al. The role of biomarkers in the diagnosis and treatment follow-up of idiopathic pulmonary fibrosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2024; 41 (2): e2024015. DOI: 10.36141/svdld.v41i2.15454.

16. Ejima M., Okamoto T., Suzuki T., Miyazaki Y. Role of serum surfactant protein-D as a prognostic predictor in fibrotic hypersensitivity pneumonitis. Respir. Investig. 2022; 60 (3): 369–378. DOI: 10.1016/j.resinv.2021.12.003.